Our Race for a COVID-19 Therapeutic

Since January 25, 2020, a group of Distributed Bio employees has worked tirelessly to engineer a treatment for the novel COVID-19 coronavirus. When San Francisco and then California issued a shelter-in-place ordinance, our team members volunteered to brave the pandemic, worked in shifts on nights and weekends to complete the medicine.

 

Our strategy was to engineer a panel of anti-SARS antibodies to make them recognize and block the novel coronavirus. The result of that work is a panel of ultra-high affinity therapeutic antibodies to neutralize SARS-CoV-2 (the virus behind COVID-19). The work leveraged both the Distributed Bio SuperHuman 2.0 human antibody discovery technology and the Tumbler computational antibody optimization technology to discover thousands of antibodies against a novel virus in 9 weeks. Stay tuned on social media and take a look below for more information on the COVID-19 pandemic and our therapeutics program.

Fundamentally, we think that national governments should pay for anti-COVID-19 therapeutics to reach the world, but this is a crisis and we need to move fast, so if you have some money you don’t need, you can donate below and we will put it to good use (and report openly about exactly what we do with it). Either way, please spread the word and contact your representatives.

Due to the high number of press releases we've decided to feature them all on our dedicated news page. You can find it here.

Also make sure to check out our Centivax Covid-19 for updates!

Last updated: May 28, 2020

The Distributed Bio Covid19 Team: Success!!!

Mar 31, 2020

press-release-covid19-20200401_Square.pn

The Distributed Bio Covid19 Team at Work

Mar 26, 2020

Dr. Glanville on CNBC

Mar 23, 2020

Dr. Glanville on Fox

Mar 19, 2020

Dr. Glanville on CBS 8 San Diego

Mar 18, 2020

Dr. Glanville on FOX Business

Mar 18, 2020

Dr. Glanville on MSNBC

Mar 14, 2020

(415) 489-0246

201 Gateway Blvd, Floor 1

 South San Francisco, CA 94080, USA